Table 1	Return to article
Figure 1	Return to article
Fig. 1 Vertical scatter plots demonstrating absolute gene expression levels in individual tumors and benign glands from the initial microarray profiles. In all cases, the lower expression threshold is 70.8, representing the scaled noise of the noisiest GeneChip in the experiment. Scaled average difference values less than the threshold were adjusted to 70.8 and, therefore, overlap. A, genes that vary in tumors relative to normal glands. B, expression levels of Cdk10, serotonin receptor 2B, and Pgm-5 plotted with a reduced Y axis to better demonstrate their ranges of expression. C, genes that vary in metastases relative to primary tumors. Symbols correspond to specific pathological descriptions: A and B, , tumor; , benign; C , metastasis; , primary tumor. Horizontal bars average gene expression in each respective sample set.
Figure 2	Return to article
Fig. 2. Vertical scatter plots demonstrating relative expression levels for hepsin and Pgm-5 in an independent set of malignant and nonmalignant samples. By quantitative RT-PCR, these two genes both exhibited significant (P<0.01 and P<0.05, respectively) expression differences between malignant and nonmalignant samples in the validation sample set. Horizontal bars, average expression of hepsin and Pgm-5 in malignant and nonmalignant samples sets.
Figure 3	Return to article
	Fig. 3. In situ hybridization for hepsin expression in the prostate. H&E stains of an adjacent frozen section are shown at right A and B, a low-power view of a prostate specimen with both benign (arrows) and malignant (arrowhead) epithelia. Hepsin is specifically overexpressed in malignant glands. C and D, a high-power view of malignant prostate epithelia overexpressing hepsin. E and F, a high-power view of PIN lesions that also overexpress hepsin. G and H, a high-power view of benign epithelia within the cancer specimen. Note that the benign glands do not express hepsin at appreciable levels.